BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 37,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 37,000 shares of BioNTech stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00. Following the completion of the transaction, the chief executive officer directly owned 744,709 shares in the company, valued at approximately $73,875,132.80. This trade represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Down 0.5%

BioNTech stock traded down $0.53 during midday trading on Wednesday, reaching $98.13. The stock had a trading volume of 706,871 shares, compared to its average volume of 1,112,188. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a market cap of $24.82 billion, a price-to-earnings ratio of -12.53 and a beta of 1.29. The firm’s fifty day simple moving average is $96.94 and its two-hundred day simple moving average is $95.55.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.60) earnings per share. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in shares of BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after acquiring an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of BioNTech during the 1st quarter valued at about $167,000. Russell Investments Group Ltd. raised its stake in shares of BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after acquiring an additional 11,064 shares in the last quarter. Natixis bought a new position in shares of BioNTech in the 2nd quarter valued at approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after purchasing an additional 13,788 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BNTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Canaccord Genuity Group lowered their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Citigroup dropped their target price on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Berenberg Bank decreased their price target on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $126.00.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.